Stocks in Play: Zenith Epigenetics Ltd.

Thursday, April 22, 2021

12:01 PM EST – Zenith Epigenetics Ltd. : Has entered into an agreement with Astellas Pharma Inc. to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide), in patients with metastatic castration resistant prostate cancer (mCRPC). Zenith Epigenetics Ltd. (T.RVX) shares were up $0.02 at 0.93.

Stocks in Play: Zenith Epigenetics Ltd., Thu, 22 Apr 2021 12:12:05 EST

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire